Premium
Valproate‐Induced Systemic Lupus Erythematosus in a Patient with Partial Trisomy of Chromosome 9 and Epilepsy
Author(s) -
Gigli Gian Luigi,
Scalise Anna,
Pauri Flavia,
Silvestri Giulia,
Diomedi Marina,
Placidi Fabio,
Pomponi Maria Grazia,
Masala Cesare
Publication year - 1996
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1996.tb00614.x
Subject(s) - discontinuation , medicine , epilepsy , anti nuclear antibody , trisomy , immunology , gastroenterology , antibody , biology , autoantibody , psychiatry , genetics
Summary: We report a mentally retarded 30–year‐old woman with partial trisomy of chromosome 9 (46,XX6,+der(6)t(6,9)pat) who has had epilepsy since age 11 months. She had been treated with various combinations of drugs. After 1 year of treatment with valproate (VPA) and ethosuximide (ESM), the patient developed arthral‐gias, muscle weakness, fatigue, and fever. Laboratory examination showed increased sedimentation rate, hyper‐gammaglobulinemia, and high titers of antinuclear antibodies (ANA). The possibility of VPA‐induced systemic lupus erythematosus (SLE) was considered. This diagnosis was supported by detection of antihistone antibodies and the HLA‐DR4 antigen. VPA dosage was tapered and discontinued, with accompanying resolution of clinical, immunological and hematological signs of SLE 6 weeks after VPA discontinuation. This is the fourth reported case of VPA‐induced SLE.